Characterization of the Second Apoptosis Inhibitor Encoded by Guinea Pig Cytomegalovirus

Keisuke Satoh1, Keita Takahashi1, Kazuma Noguchi1

  • 1Microbiology & Immunology, Gifu Pharmaceutical University, Gifu, Japan.

Journal of Virology
|December 6, 2022
PubMed

Insights

Guinea pig cytomegalovirus (GPCMV) has a second apoptosis inhibitor, gp38.3-2, which interacts with the proapoptotic protein BAK. This finding advances understanding of viral evasion mechanisms and potential therapeutic strategies.

Area of Science:

  • Virology
  • Immunology
  • Molecular Biology

Background:

  • Guinea pig cytomegalovirus (GPCMV) is a model for congenital CMV infection.
  • Viral mechanisms for evading host defenses, particularly apoptosis, are not fully understood.
  • Previous work identified GPCMV gp38.1 as a weak inhibitor of apoptosis.

Purpose of the Study:

  • To identify and characterize additional GPCMV proteins involved in apoptosis evasion.
  • To investigate the interaction of GPCMV gp38.3-2 with host cell apoptosis pathways.
  • To assess the in vivo and in vitro roles of gp38.3-2 in viral pathogenesis.

Main Methods:

  • Sequence analysis and comparison with murine CMV (MCMV) m41.
  • Apoptosis inhibition assays using staurosporine.
  • Three-dimensional protein complex prediction and mutant analysis.
  • Infection of guinea pig fibroblast cells and assessment of viral yields.
  • Analysis of monocyte, macrophage, and whole guinea pig infection.

Main Results:

  • gp38.3-2, a 42-amino acid protein, showed similarity to MCMV m41.1.
  • gp38.3-2 inhibited staurosporine-induced apoptosis by interacting with BAK's BH3 and BH1 motifs.
  • GPCMV lacking gp38.3-2 (Δ38.3-2) showed earlier cell death and reduced viral yields.
  • Δ38.3-2 exhibited decreased infection of monocytes and macrophages.
  • No significant difference in infection was observed in whole guinea pigs.

Conclusions:

  • gp38.3-2 is a novel GPCMV apoptosis inhibitor that targets BAK.
  • The gp38.3-2 interaction with BAK is structurally unique.
  • gp38.3-2 plays a role in cell apoptosis and monocyte/macrophage infection in vitro.
  • gp38.3-2 appears to contribute minimally to host defense evasion in vivo under tested conditions.
  • Findings suggest potential for developing BH3 mimetic therapeutics based on short peptides.